Name: UNCY Income Statement - Unicycive Therapeutics Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

UNCY - Unicycive Therapeutics, Inc.

USD | NASDAQ | Healthcare

UNCY Income Statement - Unicycive Therapeutics Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20
Revenues
Revenues	-	-	-	-	-	-	-	-	-	-	-	-	0.7	-	1.0	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues
Revenues	-	-	-	0.7	1.0	-	-
Cost of Revenue	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-
Operating Expenses
Research & Development	8.6	9.1	20.0	12.9	12.4	6.1	1.0
Selling General & Administrative	-	-	-	-	0.4	0.2
Operating Income
Operating Income	(30.0)	(29.5)	(32.1)	(20.8)	(18.1)	(9.0)	(2.0)
Non-Operating
Interest Income	1.2	1.0	1.3	0.6	-	-	-
Interest Expense	-	0.1	0.1	0.1	0.0	0.6	0.2
Tax & Net
Income Tax Expense	-	-	-	-	-	-	-
Net Income From Continuing Ops	(39.9)	(26.6)	(36.7)	(30.5)	(18.1)	(10.0)
Per Share
EPS Basic	(1.67)	(1.67)	(5.65)	(1.28)	(1.20)	(0.86)	(0.27)
EPS Diluted	(1.67)	(1.67)	(5.65)	(1.28)	(1.20)	(0.86)	-
Supplementary Data
EBITDA	-	(29.5)	(32.1)	(20.8)	(17.6)	(8.5)	(2.0)
EBIT	(30.0)	(29.5)	(32.1)	(20.8)	(18.1)	(9.0)	(2.0)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	1.6	2.2	3.0	1.8	2.2	5.3	3.0	4.9	6.8	4.2	3.4	2.3	3.0	3.8	4.8	1.9	1.9	1.4	3.8	0.5	0.5	-	0.3	0.2	-
Selling General & Administrative	-	-	-	-	-	-	-	-	-	-	0.5	0.2	0.1	(0.0)	0.2	0.1
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	6.8	5.0	4.4	5.2	5.8	4.0	3.2	2.5	2.4	2.1	2.6	2.1	1.8	1.5	1.7	1.8	1.6
Depreciation & Amortization	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-
Amortization of Intangibles	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	1.6	0.5	(10.4)	-	(0.0)	-	-
Total Operating Expenses	8.4	7.2	7.3	7.0	8.0	9.3	6.3	7.4	9.2	6.3	5.9	4.3	4.9	5.3	6.5	3.6

Operating Income
Operating Income	(8.4)	(7.2)	(7.3)	(7.0)	(8.0)	(9.3)	(6.3)	(7.4)	(9.2)	(6.3)	(5.9)	(4.3)	(4.2)	(5.3)	(5.6)	(3.6)	(3.5)	(2.8)	(4.7)	(0.8)	(0.7)	-	(0.6)	(0.3)	-

Tax & Net
Income Tax Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income From Continuing Ops	(12.8)	(14.7)	(6.0)	(6.4)	0.6	(21.5)	(4.1)	9.9	(21.0)	(7.8)	(4.3)	(3.8)	(14.6)	(5.3)	(5.6)	(3.6)	(3.5)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	(12.8)	(14.7)	(6.0)	(6.4)	0.6	(21.5)	(4.1)	9.9	(21.0)	(7.8)	(4.3)	(3.8)	(14.6)	(5.3)	(5.6)	(3.6)	(3.5)
Net Income Attributable To Parent	(12.8)	(14.7)	(6.0)	(6.4)	0.6	(21.5)	(4.1)	9.9	(21.0)	(7.8)	(4.3)	(3.8)	(14.6)	(5.3)	(5.6)	(3.6)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	0.9	0.2	0.0	0.1	0.6	0.2	-	-	-	-
Net Income To Common Shareholders	(12.8)	(14.6)	(6.0)	(6.4)	0.5	(15.6)	(4.1)	3.0	(21.2)	(7.8)	(4.4)	(4.4)	(14.8)	(5.3)	(5.6)

Per Share
EPS Basic	(0.54)	-	(0.33)	(0.52)	0.04	-	(0.46)	0.80	(0.61)	-	(0.13)	(0.29)	(0.97)	-	(0.37)	(0.24)	(0.24)	-	(0.37)	(0.13)	(0.11)	-	-	-	-
EPS Diluted	(0.54)	-	(0.33)	(0.52)	(0.50)	-	(0.46)	(1.50)	(0.61)	-	(0.13)	(0.29)	(0.97)	-	(0.37)	(0.24)	(0.24)	-
Shares Basic	23.9	-	18.1	12.3	11.7	-	8.9	3.8	34.9	-	32.6	15.2	15.2	-	15.1	15.0	15.0	-
Shares Diluted	23.9	-	18.1	12.3	12.4	-	8.9	9.4	34.9	-	32.6	15.2	15.2	-	15.1	15.0	15.0	-

Supplementary Data
EBITDA	(8.4)	-	-	-	(8.0)	-	-	-	(9.2)	-	-	-	(4.2)	-	-	-	(3.5)	-	-	-	-	-	-	-	-
EBIT	(8.4)	(7.2)	(7.3)	(7.0)	(8.0)	(9.3)	(6.3)	(7.4)	(9.2)	(6.3)	(5.9)	(4.3)	(4.2)	(5.3)	(5.6)	(3.6)	(3.5)	(2.8)	(4.7)